To establish a Biotechnology Management Office in the Department of Defense and to provide support for the research and development of bioindustrial manufacturing processes, and for other purposes.
HB6664 would create a Biotechnology Management Office within the Department of Defense and require the Secretary of Defense to designate a senior official with biotechnology experience to lead it. The office would be responsible for developing and maintaining a long-term roadmap for biotechnology research, development, acquisition, and sustainment; updating internal DoD policies for adopting biotechnology-based products; coordinating with other federal agencies, industry, academia, international partners, and state and local governments; and identifying workforce and training gaps. The bill also requires a briefing to congressional defense committees on the office’s charter and early implementation plans, and the office would sunset on September 30, 2030.
In addition, the bill amends existing law governing bioindustrial manufacturing support in the National Defense Authorization Act for Fiscal Year 2023. It clarifies that Department of Defense research, development, test, and evaluation funds may be used for activities supporting bioindustrial manufacturing, including design and construction activities. The measure is aimed at strengthening the Pentagon’s ability to develop and adopt biotechnology capabilities and to support related manufacturing infrastructure.
The bill’s impact on state laws is indirect rather than regulatory: it does not create or preempt state law, but it explicitly encourages collaboration with state and local government partners and regional innovation ecosystems. Its main legal effect is within federal defense authorities, where it creates a new organizational structure and broadens the use of DoD RDT&E funds for bioindustrial manufacturing-related work.
Because there are no recorded committee transcripts or votes in the provided material, there is no documented floor or committee sentiment to assess beyond the bill’s text. The overall tone of the legislation is affirmative and strategic, reflecting support for biotechnology modernization, defense readiness, and public-private coordination. No opposition is shown in the available record.
Notable points of contention are not documented in the provided materials, but potential areas of debate could include the scope of the new office, whether the Department of Defense should take a leading role in biotechnology policy and acquisition, how much discretion the senior official should have, and whether defense funds should be used for design and construction activities tied to bioindustrial manufacturing. The bill’s sunset provision may also reflect an effort to limit the office’s duration and allow future review of its effectiveness.
The bill would create a new Biotechnology Management Office inside the Department of Defense, establish a senior biotechnology official, and authorize the office to coordinate policy, acquisition, workforce, and partnership efforts related to defense biotechnology. It also amends existing defense authorization law to permit RDT&E funds to support bioindustrial manufacturing activities, including design and construction, thereby expanding the range of federally funded biotechnology infrastructure and development efforts within DoD.
No committee discussion or vote history was provided, so there is no recorded public sentiment to summarize. Based on the bill text alone, the measure appears broadly supportive of biotechnology development for national defense purposes, with an emphasis on modernization, coordination, and long-term planning. The available record does not show formal opposition or support from members.
The provided materials do not identify any specific contention, amendments, or objections. Potential issues that could draw debate include whether the Department of Defense should centralize biotechnology oversight in a new office, how much authority the office should have over acquisition and policy changes, the use of defense research funds for bioindustrial manufacturing design and construction, and the extent of coordination with private industry, academia, and state and local partners.